The induction of apoptosis, inhibition of tumour growth and cell invasion, and cell cycle arrest were other promising results obtained after Src inhibition with saracatinib in cell lines of head and neck squamous cell carcinoma, lymphoma, and colorectal cancer [32,33,34]. This evidence concerns the gene SRC and lymphoma.